co-exhibiting companies and partners...epidermis platform are developed to screen new molecular...

FRENCH PAVILION BOOTH N° 527BIO BOSTON, JUNE 4-7

CO-EXHIBITING COMPANIES

AND PARTNERS

TABLE OF CONTENTS

2

CO-EXHIBITING COMPANIES AND PARTNERSALAXIA ............................................................................05

ALIZÉ PHARMA 3 ...........................................................06

ANS BIOTECH ................................................................07

APTYS .............................................................................08

BIOASTER .......................................................................09

CEA LETI ........................................................................10

CYNBIOSE .......................................................................11

CYTOO .............................................................................12

ENYO PHARMA ..............................................................13

FAB'ENTECH ..................................................................14

GENOWAY .......................................................................15

INDICIA PRODUCTION ..................................................16

INNOPAIN .......................................................................17

INOVOTION .....................................................................18

ICARE ..............................................................................19

LXREPAIR .......................................................................20

NOSOPHARM .................................................................21

NOVADISCOVERY ..........................................................22

ORPHELIA PHARMA .....................................................23

OSIVAX ............................................................................24

SIGNIA THERAPEUTICS ...............................................25

SYNAPCELL ...................................................................26

SOLADIS .........................................................................27

THERANEXUS ................................................................28

TRANSCURE BIOSERVICES .........................................29

VOXCAN ..........................................................................30

LIFE SCIENCES IN AUVERGNE-RHÔNE-ALPES Lyonbiopole, the gateway to healthcare innovation …………………………………………………………………………………………… 33

Accinov, Biomanufacturing THE OPEN WAY………………………………………………………………………………………………………… 35

Only Lyon, Life Sciences a driving force for Lyon's economy ……………………………………………………………………………… 37

Biopole Clermont Limagne ………………………………………………………………………………………………………………………………… 39

3

CO-EXHIBITING COMPANIESAND PARTNERS

ECONOMIC PLAYERS

This year in Boston,

representing the industrial & scientific strengths of the Auvergne-Rhône-Alpes region, under the banner of Lyonbiopole.

26

Alaxia and its partner Stragen develop innovative therapeutics ALX-009 and

STR-324.

ALX-009 is a first-in-class antimicrobial wide spectrum product targeting to

kills bacteria including antibiotic resistant strains and to compensate deficient

innate lung defense system in Cystic Fibrosis. Other than the killing properties,

the potential of ALX-009 resides in its particular mode of action not generating

resistance. Clinical trial with CF patients is currently ongoing.

STR-324 is a first-in-class non-opioid painkiller with a safe, non-addictive and

innovative mode of action DENKI based for various pain indications including

neuropathic pain. Clinical trial is currently ongoing.

5

Contact: Philippe BORDEAU

VP INNOVATION & BUSINESS DEVELOPMENT

60, avenue Rockefeller - Bâtiment Adenine

F - 69008 LYON

Tel: +33 (0)4 37 53 26 37 - +33 (0)6 08 52 26 31

E-mail: [email protected]

www.alaxia-pharma.eu

6

Contact: Thierry ABRIBAT

PRESIDENT & CEO

15, chemin du Saquin - F - 69130 ECULLY

Tel: +33 (0)4 72 18 94 28


www.alz-pharma.com

Alizé Pharma 3 is focused on developing innovative therapeutics for rare

diseases.

Our first asset is AZP-3404, a short stabilized peptide derived from IGFBP-2,

a physiological protein that has been shown to regulate bone, fat and glucose

metabolism. On bone, it is a key regulator of osteoblasts differentiation. AZP-

3404 is at the preclinical stage for the treatment of osteogenesis imperfecta, a

rare bone disease, and has the potential to also address unmet clinical needs

in additional metabolic and musculoskeletal indications.

Our strategy is to acquire additional programs to build a leading biopharma

in rare diseases with both European and US presence to support global

developments.

7

Contact: François CAUSSADE

CEO

20/22, rue Henri et Gilberte Goudier - F - 63200 RIOM

Tel: +33 (0)9 70 75 85 03 - 33 (0)6 80 17 03 50


www.ans-biotech.com

ANS Biotech, a preclinical CRO dedicated to the in vivo pharmacology of pain,

offers a unique combination of exceptional expertise in the fundamentals of

pain pharmacology and a proven record of R&D program management for the

new and innovative analgesics of its clients.

Our mission is to support the drug discovery and development efforts of

companies involved in human and animal health, food and nutrition, by offering

a broad range of consulting services and a growing list of clinically relevant

disease and efficacy models.

As a close Pharma and Biotech partner, we commit to providing cost-effective

preclinical pharmacology services performed to the highest ethical and quality

standards. Our customized scientific studies can help to establish proof of

concept & mechanism of action for drug candidates.

8

Contact: Michel LEPERS

BUSINESS DEVELOPMENT MANAGER

Biopôle Clermont-Limagne - F - 63360 SAINT-BEAUZIRE

Tel: +33 (0)4 73 67 06 70 - +33 (0)6 80 05 70 22


www.aptys-pharmaceuticals.com

APTYS develops innovative products based of its expertise in formulation.

We deliver a ready to use package (formula and manufacturing process,

validated analytical methods and stability data).

Our offer: custom-made formulations; analytical development and validation;

quality control and ICH stability; in vivo/in vitro assessments.

Our skills: topical and transdermal delivery, peptide delivery, transmucosal

delivery.

Track record: new transdermal gel of testosterone (phase III); generic of inhaled

product (market); injectable depot of a peptide (pre clinic); generic of injectable

buccal anesthetic (industrialization); buccal solution for trans-mucosal delivery

(phase I); oral combo dosage form (Phase III).

Quality: APTYS is ISO9001-2015 certified and holds GMP license from the

French Agency.

9

Contact: Jérémie LANGLET

STRATEGIC PARTNERSHIP MANAGER

40, avenue Tony Garnier - F - 69007 Lyon

Tel: +33 (0)4 69 85 19 20 - +33 (0)6 16 26 57 29


www.bioaster.org

BIOASTER was created in April 2012 by the Institut Pasteur and Lyonbiopole

health competitiveness cluster, following the initiative of the French government.

We have developed a unique technological and innovative model to support

the latest challenges in microbiology, in particular to fight antimicrobials

resistance, improve vaccines safety and efficacy, quickly diagnose infections at

patient bedside and take full advantage of human and animal microbiota.

BIOASTER’s 120 staff members come equally from industries & academics;

the large majority are scientists and engineers originating from 17 different

citizenships. We drive new technologies innovation in our own infrastructures

with state of the art equipment and privileged access to the French National

Physics Computing Centre and the Jean Mérieux BSL4 laboratory.

10

Contact: Alexandre THERMET

NORTH AMERICA MANAGER,

STRATEGIC INDUSTRIAL PARTNERSHIPS

CEA Leti-Health dpt @ Business France Agency

88 Kearny Street, Suite 700 - US - CA 94108 SAN FRANCISCO

Tel: 1 (510) 331 3859


www.cea-leti.fr

Leti is a technology research institute at CEA Tech. LETI-Health regroups 250

researchers, technicians, engineers and clinicians working in the Technology

for Biology and Health Department and Clinatec, a novel pre-clinical and

clinical platform developed with the University hospital.

Together with our industrial, clinical and academic partners, we address

the following application domains: in vitro diagnostics and monitoring for

health, environment, life science, manufacturing and CBRN, therapeutics,

nanomedicine and implanted medical devices and imaging systems.

Our strategy is to serve the industry and answer to the health challenges,

going toward miniaturization, multi-modality and connected devices, delivering

prototypes “ready to transfer”, i.e. compliant with industrial standards and

medical regulations.

11

Contact: Hugues CONTAMIN

CEO

1, avenue Bourgelat - F - 69280 MARCY L'ETOILE

Tel: +33 (0)4 78 51 20 89 - +33 (0)6 62 74 35 66


www.cynbiose.com

Cynbiose is a unique biotechnology company that aims to set-up and market

innovative Non Human Primate (NHP) models to accelerate the development

of immunotherapies.

Supporting by a highly technically qualified and controlled application platform,

Cynbiose offers a large selection of pharmacological NHP products to explore,

analyse, and evaluate the pharmacokinetic and the efficacy of immunotherapies.

Cynbiose works side by side with its partners to provide the best possible

support on their projects in order to better orient for optimal decisions and

thus create values.

Cynbiose wants to make sense of the technologies, products and services

provided to its clients, convinced that the quality of the relationships and the

pooling of expertise are essential levers for the success of a project.

12

Contact: Christophe POQUET

BUSINESS DEVELOPMENT MANAGER

7, parvis Louis Néel - Minatec, bht, bat. 52

F - 38040 GRENOBLE

Tel: +33 (0)4 38 88 47 05 - +33 (0)6 47 27 33 81


www.cytoo.com

CYTOO is a preclinical stage Drug Discovery company addressing muscular

disorders. Using MyoScreen™, a first-in-class drug discovery engine for High

Content Screening, CYTOO brings its R&D platform and lead compounds to

discover, profile and develop new effective therapies against muscle wasting

(sarcopenia, cachexia) and genetic myopathies (e.g. DMD).

CYTOO also offers early stage drug discovery capabilities in the field of skin

disorders. Skin inflammation models derived from the EpiScreen™ micro-

epidermis platform are developed to screen new molecular entities active

against Psoriasis and Atopic Dermatitis.

These muscle and skin models are already used by the pharmaceutical,

dermato-cosmetic, nutraceutical, food processing and animal health sectors

for screening of biologically active compounds.

1313

Contact: Tatiana DANTHENY

CEO PROJECT ASSISTANT

Bâtiment Domilyon - 321, avenue Jean Jaurès

F - 69007 LYON

Tel: +33 (0)4 37 70 02 27


www.enyopharma.com

ENYO Pharma is a biopharmaceutical company which has developed an

innovative drug discovery engine inspired by viruses to identify first-in-class

chemistries. The key of this approach based on biomimetism is to identify the

right protein-protein interactions (PPIs) to mimic the virus strategy.

Our main candidate EYP001 is an FXR agonist about to enter phase 2 for both

HBV and NASH. Our second candidate, EYP002, is currently in preclinic. Initially

developed against influenza virus, it has a mitochondrial cellular target which

leads ENYO to explore new indications such as oncology and metabolic diseases.

The company has also received funding from the EU H2020 programme for its

MIMESIS project, to scale-up its drug discovery engine in various therapeutic

areas following the successful proof-of-concept with EYP002.

14

Contact: Raphaël METROP

HEAD OF CORPORATE BUSINESS DEVELOPMENT

24, rue Jean Baldassini - F - 69007 LYON

Tel: +33 (0)4 37 70 67 67


www.fabentech.com

Fab'entech is a privately-owned company developing and manufacturing

polyclonal immunotherapies to address situations of emergency.

After having successfully developed Fabenflu®, a treatment of H5N1 infections

in human, Fab'entech is now focusing on intoxications with antidote candidates

in the fields of biodefense (in collaboration with the French Army) and drug

intoxication (in collaboration with a private industrial partner).

Based on this strategy, which will make the company become sustainable by

2022, Fab'entech is also currently securing a Series-B fundraising.

Today, Fab'entech wants to leverage on these preliminary successes, and is

therefore seeking new industrial partners to collaborate on the development

of its biodefense asset, and on the development of antidotes in additional

indications as well.

15

Contact: Kader THIAM

VP TRANSGENIC TECHNOLOGIES

31, rue Saint Jean de Dieu - F - 69007 LYON

Tel: +33 (0)4 37 65 41 00


www.genoway.com

For 19 years, genOway has been engaged to improve the quality & predictibility

of preclinical strategies. Our strong expertise lies in the design of the model

which is key to preserve the biology of the target and to develop physiologically

relevant models. The company holds exclusive IP on key technologies and

deliver models with all required FTO.

We partner with 15 of the Top 20 Pharmas, Biotechs and academic researchers

worldwide in many therapeutic areas (oncology, immunology etc.).

We provide access to customized and to catalog models. Our humanized

platform is aiming at increasing the translability towards human physiology for

better predictability of PK/PD studies (Hu-FcRn/Hu-HSA), specific compound

efficacy (Hu-CD4, Hu-TNF-α) and Immune checkpoints modulation (Hu-VISTA,

Ox40, PD-1, CTLA-4, GITR, SIRPα...).

16

Contact: Stéphane LEGASTELOIS

PRESIDENT

ZA La Parliere - F - 69610 ST GENIS

Tel: +33 (0)4 74 72 36 10 - +33 (0)6 80 75 89 46


www.indicia.fr

Indicia Production, a CMO of 60 employees, offers GMP industrial production

services to Life Science companies wishing to outsource their formulation and

aseptic filling of culture media, reagents and pharmaceutical excipients.

Indicia also performs customized formulation and filling of sterile liquid

medical devices (class I to III) and in vitro diagnostic products.

17

Contact: Stéphanie CAILLOUX

COO

Biopôle Clermont-Limagne - F - 63360 SAINT-BEAUZIRE

Tel: +33 (0)6 82 91 10 05


www.innopain.com

The understanding of the mechanisms of pain has significantly improved in

the recent decade, but therapeutic innovation has not yet advanced. Morphine

and opiate derivatives are still the privileged drugs used despite their negative

side effects. Scientists have studied morphine's mechanism of action and have

separated the antalgic and the side effect, discovering a new target, TREK1

Channel, and developing a NCE specific of this target. This impacting discovery

was published in Nature in 2013 after securing 2 patents.

Innopain has exclusive wordlwide license of these 2 patents and our mission is

to develop non-opioid original analgesics to replace morphine without its side

effects.

Our objective is to get the proof of concept with clinical phase II - intravenous

and oral, for acute and chronic pain.

18

Contact: Arnaud PEYRONNIER

BUSINESS DEVELOPER MANAGER

5, avenue du Grand Sablon - F - 38700 LA TRONCHE

Tel: +33 (0)4 76 54 95 12 - +33 (0)7 68 05 70 53


www.inovotion.com

We are a biotech company offering a unique, breakthrough in vivo technology

providing oncology efficacy and toxicity assays. Our Fast, Sensitive, Reliable

and Affordable assays save time and money, giving you a clear competitive

advantage.

By eliminating low-value molecules early, we accelerate your Drug Discovery

process, increase your R&D productivity and reduce your costs, allowing rapid

and solid Go/No Go decisions.

These Next-Generation in vivo efficacy and toxicity tests are available in four

main analysis areas, which can be tailored to your needs:

• EFFICACY assays for your anti-cancer treatments

• EARLY TOXICITY assays for your drug candidates

• TARGET VALIDATION in oncology

• MULTI-CANCER SCREENING to (re)positioning your treatment.

19

Contact: Ana-Lucia DA COSTA

SALES MANAGER

Biopôle Clermont-Limagne - BP 60006

F - 63360 SAINT-BEAUZIRE

Tel: +33 (0)4 73 33 99 99 – +33 (0)6 26 43 02 39


www.groupeicare.com

Our primary goal is to keep contamination of healthcare products under control

in compliance with relevant regulations through a comprehensive approach

encompassing our customers and their suppliers. We intervene when a

compagny, organistion or research facility implements a process in which there

is a risk of contamination.

Our mission is to provide our customers with an assurance that the

manufactured product or device goes to market in compliance with relevant

statutory requirements and standards.

We mainly do microbiological analyses, Validation & Qualification.

20

Contact: Sylvie SAUVAIGO

CEO

7, parvis Louis Néel - F - 38040 GRENOBLE CEDEX 9

Tel: +33 (0)4 38 78 37 52 - +33 (0)6 21 21 77 95


www.lxrepair.com

LXRepair aims at providing a new dimension to personalized medicine in

cancer by complementing genomics with functional assays to identify predictive

biomarkers of patients’ response to anticancer therapies.

Our multiplex enzymatic assays characterize complex pathways: DNA Repair,

DNA Damage Response and their kinase regulators. They are suitable for

preclinical and clinical studies.

Our internal pipeline focuses on DNA Repair / DDR defects associated with

response to immunotherapy and resistance to radio and chemotherapy. We

provide anew stratification strategy for metastatic melanoma.

First CE mark certification to predict radiotoxicity events is expected in 2020.

We provide service to Pharma companies to stratify patients and decipher

drugs efficiency and MOA (DNA Repair inhibitors, etc).

21

Contact: Philippe VILLAIN-GUILLOT

CEO

21, avenue Georges Pompidou - Danica B - F - 69486 LYON

Tel: +33 (0)4 11 71 61 85 - +33 (0)6 26 63 24 89


www.nosopharm.com

Nosopharm is an innovative biotechnology company specialized in the research

and development of new molecules to combat antimicrobial resistance (AMR).

The innovative anti-infective drug discovery platform developed by the company

is based on the therapeutic exploitation of a very original bioresource: the

bacterial genera Xenorhabdus and Photorhabdus.

Nosopharm’s pipeline focuses on the treatment of life-threatening healthcare-

associated infections. The most advanced program in the pipeline is NOSO-

502, a first-in-class Odilorhabdin antibiotic targeting the very concerning

multidrug-resistant pathogens Enterobacteriaceae (ESBL, CRE). Nosopharm

is also working on the development of additional first-in-class antimicrobials

for the treatment of systemic P. aeruginosa and Candida infections.

22

Contact: François-Henri BOISSEL

CEO

1, place Verrazzano - F - 69009 LYON

Tel: +33 (0)9 72 53 13 00 - +33 (0)6 75 48 31 81


www.novadiscovery.com

Pioneer of in silico medicine, NOVADISCOVERY enables its academic and

industrial partners to accelerate and de-risk the research and development of

new drugs by establishing their therapeutic benefit upstream of human trials.

NOVADISCOVERY's innovative approach combines mathematical models

of diseases and treatments with virtual patients in an open technological

ecosystem called WISE® (Whitebox In Silico Engine), which brings together all

the modeling and simulation expertise of the company.

Headquartered in Lyon, France, NOVADISCOVERY relies on the Effect Model, a

novel methodology discovered by Professor Jean-Pierre BOISSEL, one of the

founding fathers of systems medicine. The company has a team of scientists,

engineers and clinicians who work at the interface of systems biology,

pharmacology, meta-analysis.

23

Contact: Jérémy BASTID

CHIEF DEVELOPMENT OFFICER

85, bd Saint Michel - F - 75005 PARIS

Tel: +33 (0)1 42 77 08 18 - +33 (0)4 37 49 87 72


www.orphelia-pharma.eu

ORPHELIA Pharma is a biopharmaceutical company aiming at developing and

marketing paediatric drugs in oncology, CNS and metabolic diseases.

Our mission is to provide meaningful advances to children through the

development of efficient, reliable and easy-to-use medicines.

24

Contact: Alexandre LE VERT

CHAIRMAN AND COFOUNDER

99, rue de Gerland - F - 69007 LYON

Tel: +33 (0)4 37 65 55 03 - +33 (0)6 79 82 92 70


www.osivax.com

OSIVAX is a biotech start-up based in France (Lyon), which develops CD8 T-cell

inducing vaccines thanks to its technology platform, oligoDOM®.

OSIVAX’ lead candidate is an influenza vaccine that is about to start a phase I

clinical trial:

• Despite a $4bn Flu vaccine market, influenza is still devastating (56,000

deaths in the US only in 2014-15).

• An alternative path to improve Flu vaccine efficacy was recently described :

cellular immune response against Influenza NucleoProtein-NP).

• Osivax has a best-in-class product (OVX836) with a blockbuster potential :

OVX836 demonstrated 100% protection against multiple Flu strains in mice

& ferrets. Combined with seasonal Flu vaccines OVX836 has a blockbuster

potential (>$1B/yr).

• OVX836 is about to enter a phase I clinical trial, with a licensure expected in

2022.

25

Contact: Michel COUSINEAU

PRESIDENT

43, boulevard du 11 novembre 1918

F - 69100 VILLEURBANNE

Tel: +33 (0)4 78 77 10 37 - +33 (0)6 70 31 46 70


www.signiatherapeutics.com

Signia Therapeutics proposes a breakthrough strategy to repurpose rapidly

& at low cost marketed drugs or to recycle drugs for new antiviral indication

against respiratory viruses.

Signia Therapeutic’s drug discovery platform has demonstrated its potential with

POC established for FDA-approved drugs that were validated for anti-influenza

& anti-MERS-CoV indications. Signia Therapeutics has a further validation of

its development strategy through the clinical evaluation of repurposed drugs as

new effective antivirals.

A phase 2b clinical trial started in Dec. 2017 in order to evaluate 2 of Signia's

antiviral candidates against influenza. This clinical trial will enroll 300 severe

Flu patients with final results in Q2 2019. This milestone confirms Signia's

strategy & validates its proprietary discovery platform.

26

Contact: Corinne ROUCARD

CEO

ZAC Isiparc - Bâtiment Synergy - F - 38330 SAINT ISMIER

Tel: +33 (0)4 58 17 15 83


www.synapcell.com

SynapCell is a preclinical stage biotechnology company focused on Central Nervous System

(CNS) disorders.

Since 2005, our CRO activity supports international pharmaceutical companies in revealing the

therapeutic potential of their compounds in development.

Backed by intensive Research and Development programs, we developed Cue®, a predictive

decision-making solution that comes with a large set of assays designed for Drug Discovery

applications.

Cue® uses the power and sensitivity of Electro-Encephalography (EEG) to identify functional

biomarkers of neurological diseases in vivo, with remarkable human translatability.

Our returning customers in USA, Japan, Korea or Europe helped the company establish a unique

reputation on the market and is the basis for long-lasting successful business partnerships.

GROUP

27

Contact: Olivier SCHWARTZ

BUSINESS MANAGER

6, rue Bellecombe - F - 69006 LYON

Tel: +33 (0)4 72 83 86 70 - +33 (0)6 13 91 49 62


www.soladis.com

Soladis has 4 business units with dedicated expertise:

• SOLADIS STATISTICS, to provide statistical services for upstream needs of study

thinking/organization (methodology, design, DoE,…) and downstream needs of

data analysis (for preclinical, clinical, and non-clinical studies).

• SOLADIS DIGITAL, in charge of projects implying data science, data visualisation,

and offering specific services for the collection and analysis of web and social

network data.

• SOLADIS CLINICAL STUDIES, full-services CRO for clinical studies (protocol

writing, management of papers, recruitment, logistic, monitoring, data

management, statistics, clinical report, publication…).

• SOLADIS CONNECT, specialized in data collection through IoT, sensors and

biosensors.

28

Contact: Julien VEYS

CBDO

60, avenue Rockefeller, pépinière Laënnec - F - 69008 LYON

Tel: +33 (0)1 46 54 85 57 - +33 (0)6 37 71 57 64


www.theranexus.com

Theranexus' technology is based on the simple yet powerful idea that one can

improve the treatment of CNS disorders by combining a neuron targeting drug with

a glial targeting drug.

Based on this rational, Theranexus has developed a screening technology which led

to the identification of combinations of two marketed drugs, one being a standard of

care in the indication while the other is repositioned to modulate glial gap junctions.

The outcome of such combination is a more effective therapeutic with a brand new

IP and benefiting from the 505(b)(2) pathway in the US.

The company now has 3 combinations in development with our lead drug candidate

being THN102 for the treatment of narcolepsy and attention deficit & excessive

sleepiness in Parkinson's disease (P2 ongoing - PoC obtained in healthy volunteers).

29

Contact: Patrick NEF

CEO

Technopole Archamps, le forum

260, avenue Marie Curie - F - 74160 ARCHAMPS

Tel: +33 (0)4 56 44 81 21


www.transcurebioservices.com

Using human immune system (HIS) mouse models, TransCure bioServices

offers its expertise in preclinical services and know-how in study designs to

investigate the efficacy and immunosafety of your therapeutic molecule on 3

main plateform :

• HIV for anti-infectious drug candidates/vaccines

• Cancer for immunotherapy

• IBD for anti-inflammatory

Contact: Najet BEN SALAH

INTERNATIONAL BUSINESS DEVELOPEMENT MANAGER

1, avenue Bourgelat - F - 69280 MARCY L'ETOILE

Tel: +33 (0)4 78 19 82 20 - +33 (0)7 52 03 72 15


www.voxcan.eu

Voxcan is an innovative company for preclinical studies, with an expertise in Infectious

diseases, Oncology, Musculoskeletal disorders.Our facilities include state-of-the-

art equipment (2000 sqm animal housing, surgery blocks, BSL 2 & 3 facilities) & an

Imaging Platform (bioluminescence, µ-scanner, fluorescence). We have characterized

several animal models that can be monitored by imaging, combined with standard

clinical follow-up, histology, qPCR, FACS etc.

• Oncology & Immuno-Oncology: Large range of cancer cells / Subcutaneous,

Orthotopic

• Infectious Diseases: Bacteria, Viruses, Fungi

• Musculoskeletal disorders: osseointegration, OsteoArthrisis, Osteoporosis, etc.

We can design on-demand protocols, or propose available models, from mouse to pig.

30

NOTE

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

31

European region forscientific research

vaccine manufacturing site in Europe

jobs in healthcare

university hospitals

+3,000 clinical trials/year

public & private healthcare institutions

32,000 hospital beds in the private & public sectors

employing over 36,000 people

Major research & higher education

centerswith 20,000 students & 3,600 researchers

in life sciences

SMBs in healthcare

32

333333333

w w w . l y o n b i o p o l e . c o m

Auvergne R hône Alpes- -

m e m b e r s6 word class leaders as founders

research & clinical centers innovative companies

+ B of private money raised by yonbiopole members since 20 3

0 networ ing & scientifc eventsorgani ed & co organi edeach year by yonbiopole

FOUNDERS AND BOARD MEMBERS

BOARD MEMBERS

REPRESENTING PUBLIC RESEARCH REPRESENTING PRIVATE COMPANIES

O U R P U B L I C A N D P R I V A T E P A R T N E R S A N D F O U N D E R S

STATE AND LOCAL

SUPPORTSGOVERNMENTS

PARTNERS FOR BIO


2 organi ations hosted in 20

2 facilities

000 s m of BS 2 & BS 3 laboratories ffice space ith full operational support

00 companies supported for internationali ation, in 20

international trade missions in 20

gateways around the world

22 & projects funded since 200

,06 B of total investment20 M of public funding

nt

B I O M A N U F A C T U R I N G T H E O P E N W A Y

THE BIOMANUFACTURING CENTER FOR BIOTECH & MEDTECH COMPANIES

• Drug discovery • Process development • Cell banking• cGMP production of drug substances & drug products using microbial fermentation or cell culture • Production of class III medical devices• Fill & Finish

LABS & PILOT UNIT AS A SERVICE

cGMP compliance Flexibility Quality assurance

Release of experimental drugs

ACCINOV

HOSTED ACTIVITIES

3535

DY

KEEP CONTROL & DO IT YOURSELF

BIOMANUFACTURINGin

I

36

38

Clémence LABATLife Sciences DirectorGrand Lyon la métropole20, rue du Lac - BP 3103 - 69399 Lyon Cedex 03Phone: + 33 668 241 838 - [email protected] www.business.greaterlyon.com

LIFE SCIENCES, A DRIVING FORCE FOR LYON’S ECONOMYLyon metropolitan area is today one of Europe‘s most dynamic and attractive place in the field of Life Sciences & Health. Lyon Métropole has a wide range of responsibilities, including supporting the urban area‘s economic development with a strong emphasis on Life Sciences & Health.

Both a living place

and a business district,

Biodistrict Lyon

gathers the entire

value chain from

science… to life.

60 000

2 BILLION CLINICAL TRIALS PERFORMED each year in the Hospices Civils de Lyon

VACCINEPRODUCTIONCENTER in the world

ST1168 6 800 5 400

1 400since 2005 in Lyon, by vaccinesand diagnostics companies

EUROS INVESTED

over

LYON MÉTROPOLE HELPS COORDINATE AND DENSIFY THE LIFE SCIENCES ECOSYSTEM ON 5 PRIORITY SECTORS

A VIBRANT ECOSYSTEM

JOBS IN HEALTH &BIOTECHNOLOGIES SECTOR

Source: Acoss-Urssaf 2015 and Insee-Clap 2015

PUBLIC LABORATORIES

Researchers & Teachers-Researchers

PHD STUDENTS

Neurosciences

Nutrition

Oncology

Infectiology

E-health

40

Nutrition-Health Pharmaceutical

Cosmetics

Biotechnologies Green chemistry

Health-Beauty-Fitness Biomedical

NOTE

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

41

NOTE

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

42

43

International Trade Services: helping companies export and grow into global marketContact: Emilie Da Silva - Business Development Manager for Americas - [email protected]

www.lyon-metropole.cci.fr

Auvergne-Rhône-Alpes, the densest biocluster in EuropeContact: Elisabetta SCHENA - Project Manager - [email protected]

www.espaceentreprises.rhonealpes.fr

Invest In LyonContact: Nathalie Laurent - Life Sciences Manager - [email protected]

www.aderly.com

The bio entrepreneurs’ hubContact: Clémence Labat - Life Sciences Project Director - [email protected]

www.business.greaterlyon.com

PARTNERS

Éditi

on 2

017

© L

yonb

iopô

le -

Réa

lisat

ion:

GOPÉ

- D

esig

ned

by m

acro

vect

or/F

reep

ik

APP STORE GOOGLE PLAY STORE


BOARD MEMBERS



STATE AND LOCAL

SUPPORTSGOVERNMENTS

PARTNERS FOR BIO

HEALTHCAREINSTITUTIONS

COMPANIES & START-UPS

CONSULTANTS &SERVICE PROVIDERS

R&DPROJECTS

RESEARCHUNITS

CLINICAL RESEARCHORGANISATIONS


ownload yonbiopole s appa n d e e p i n t o u c h w i t h o u r c o m m u n i t y

M o r e t h a n 3 0 c o n t a c t s


BOARD MEMBERS



STATE AND LOCAL

SUPPORTSGOVERNMENTS

PARTNERS FOR BIO

co-exhibiting companies and partners...epidermis platform are developed to screen new molecular...

Documents